| P2093 | author name string | Taolin Yi | |
| | Daniel Lindner | |
| P2860 | cites work | Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3) | Q83213690 |
| | Targeting tyrosine kinases in cancer: the second wave | Q83854401 |
| | Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp | Q22009057 |
| | Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome | Q24291893 |
| | Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T | Q24300141 |
| | Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor | Q24318464 |
| | Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1 | Q24318884 |
| | P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 |
| | Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases | Q24519082 |
| | Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1 | Q24647567 |
| | Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer | Q24652752 |
| | Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells | Q24672163 |
| | CDC25 phosphatases as potential human oncogenes | Q28116546 |
| | The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling | Q28182148 |
| | Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences | Q28186547 |
| | Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases | Q28187894 |
| | PRL-3 expression in metastatic cancers | Q28189073 |
| | A phosphatase associated with metastasis of colorectal cancer | Q28198115 |
| | Pentamidine is an inhibitor of PRL phosphatases with anticancer activity | Q28202052 |
| | The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis | Q28202194 |
| | PRL-3 and PRL-1 promote cell migration, invasion, and metastasis | Q28208273 |
| | Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene | Q28208996 |
| | Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray | Q28218205 |
| | Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals | Q28236222 |
| | Germ-line and somatic PTPN11 mutations in human disease | Q28264474 |
| | The biology and clinical relevance of the PTEN tumor suppressor pathway | Q28272157 |
| | PRL-3 phosphatase is implicated in ovarian cancer growth | Q28275403 |
| | High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases | Q28292332 |
| | Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases | Q28302743 |
| | Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase | Q28507508 |
| | PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth | Q28571339 |
| | PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells | Q28590230 |
| | Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation | Q28594140 |
| | Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1 | Q28609564 |
| | Protein tyrosine phosphatases: from genes, to function, to disease | Q29614826 |
| | The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. | Q30304514 |
| | Structurally unique inhibitors of human mitogen-activated protein kinase phosphatase-1 identified in a pyrrole carboxamide library | Q33286240 |
| | Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells | Q33781066 |
| | Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. | Q33886525 |
| | Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases | Q33947049 |
| | Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development | Q34110887 |
| | How do inhibitory phosphatases work? | Q34158953 |
| | Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma | Q34159084 |
| | Mutational analysis of the tyrosine phosphatome in colorectal cancers | Q34322220 |
| | Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin's lymphoma-specific genes | Q34520636 |
| | PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity | Q34522913 |
| | Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells | Q36011208 |
| | MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock | Q36227887 |
| | PRL phosphatases as potential molecular targets in cancer | Q36308640 |
| | Cytokine-based therapy and biochemotherapy for advanced melanoma | Q36445957 |
| | Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications | Q36451138 |
| | Diverse physiological functions for dual-specificity MAP kinase phosphatases | Q36648553 |
| | Activation, coactivation, and costimulation of resting human natural killer cells | Q36652166 |
| | Protein tyrosine phosphatase function: the substrate perspective | Q36713273 |
| | MAPK phosphatases--regulating the immune response | Q36743545 |
| | Cdc25 phosphatases: structure, specificity, and mechanism | Q36747424 |
| | Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. | Q36813436 |
| | Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. | Q36819391 |
| | CDC25 phosphatases in cancer cells: key players? Good targets? | Q36849329 |
| | PRL-3: a metastasis-associated phosphatase in search of a function | Q36857885 |
| | Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance | Q40136474 |
| | HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer | Q40161763 |
| | Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance | Q40236303 |
| | Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis | Q40250297 |
| | Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors | Q40306346 |
| | Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages | Q40354225 |
| | Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis | Q40533593 |
| | Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells | Q40536866 |
| | Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines | Q40781863 |
| | Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis | Q40920340 |
| | The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases | Q41056278 |
| | Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency | Q41570741 |
| | Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia | Q41772799 |
| | Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. | Q42205530 |
| | TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. | Q42470536 |
| | Abnormal Th1 cell differentiation and IFN-gamma production in T lymphocytes from motheaten viable mice mutant for Src homology 2 domain-containing protein tyrosine phosphatase-1. | Q42472588 |
| | Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors | Q42493757 |
| | Anticancer activity of sodium stibogluconate in synergy with IFNs | Q44209327 |
| | Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer | Q44346549 |
| | Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells | Q44477962 |
| | The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer | Q44888656 |
| | Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. | Q46709580 |
| | Review: Milstein Award lecture: interferons and cancer: where from here? | Q46718007 |
| | Mitogen-activated protein kinases and apoptosis in PIN. | Q47915429 |
| | Mammalian SH2-containing protein tyrosine phosphatases | Q48064947 |
| | Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene | Q48111435 |
| | Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. | Q53572786 |
| | Footprinting studies on the sequence-selective binding of pentamidine to DNA | Q68841897 |
| | Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev) | Q69735318 |
| | Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis | Q73017413 |
| | Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice | Q73023817 |
| | Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice | Q73028631 |
| | Identification of a gene expression signature associated with pediatric AML prognosis | Q73372374 |
| | Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction | Q73496882 |
| | Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling | Q73812477 |
| | Abnormal development and differentiation of macrophages and dendritic cells in viable motheaten mutant mice deficient in haematopoietic cell phosphatase | Q74321483 |
| | Signaling by the cytokine receptor superfamily | Q77934807 |
| | PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo | Q79834031 |
| | Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase | Q79880475 |
| P433 | issue | 2 | |
| P304 | page(s) | 114-121 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | The role and target potential of protein tyrosine phosphatases in cancer | |
| P478 | volume | 10 | |